References: 1. Williams RE et al. Expert opinion on the management of CLN2 disease. Poster session presented at: The 12th Annual WORLD Symposium; February – March 2016; San Diego, CA. 2. Johannsen J et al. Considering valproate as a risk factor for rapid exacerbation of complex movement disorder in progressed stages of late-infantile CLN2 disease. Neuropediatrics. 2016;47:194-196. 3. Chang M et al. CLN2. In: Mole S, Williams R, and Goebel HH, eds. The neuronal ceroid lipofuscinoses (Batten Disease). 2nd ed. Oxford, United Kingdom: Oxford University Press; 2011:80-109. 4. Mole SE and Williams RE. Neuronal ceroid – lipofuscinoses. 2001 Oct 10 [Updated 2013 Aug 1]. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews®.